You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
步長製藥(603858.SH):左乙拉西坦注射用濃溶液、阿哌沙班片獲得藥品註冊證書
格隆匯 10-18 15:35

格隆匯10月18日丨步長製藥(603858.SH)公佈,公司全資子公司通化谷紅製藥有限公司近日收到國家藥品監督管理局核准簽發的關於左乙拉西坦注射用濃溶液的《藥品註冊證書》以及全資子公司保定天浩製藥有限公司收到國家藥品監督管理局核准簽發的關於阿哌沙班片的《藥品註冊證書》。

左乙拉西坦注射用濃溶液主要用於成人及4歲以上兒童癲癇患者部分性發作(伴或不伴繼發性全面性發作)的治療。本品可在患者暫時無法應用口服制劑時替代給藥。

根據米內網數據2018年至2020年中國(城市公立,城市社區,縣級公立,鄉鎮衞生)樣本醫院年度銷售趨勢顯示,左乙拉西坦注射用濃溶液銷售額依次為50萬元、2478萬元、6339萬元。

截至公吿日,公司在左乙拉西坦注射用濃溶液上投入的研發費用約為682.27萬元。

阿哌沙班片主要用於髖關節或膝關節擇期置換術的成年患者,預防靜脈血栓栓塞事件(VTE)。

根據米內網數據2018年至2020年中國(城市公立,城市社區,縣級公立,鄉鎮衞生)樣本醫院年度銷售趨勢顯示,阿哌沙班片銷售額依次為3175萬元、5394萬元、11047萬元。

截至公吿日,公司在阿哌沙班片上投入的研發費用約為876.01萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account